61. Introduction: Why Immune Disease Requires a Deeper Clinical Grammar
14718.13 Clearance Without Overload
72. Observer Humility: Distinctions as Instruments, Not Possessions
14818.14 Transition to Exposure, Epidemiology, and Modern Niche Incoherence
83. From Observer-Centered Immunology to Organism-Centered Immune Coherence
149Part VI. Exposure, Epidemiology, and Modern Niche Incoherence
9Part II. The Immune System as 5E Organismic Cognition
15019. Anti-Salugenic Exposure-Locks and the Exposome
104. Immune Cognition as Embodied, Embedded, Enactive, Extended, and Evaluative
15119.1 The Exposome as Organism–Niche History
114.1 Embodied Immunity
15219.2 Pollutants and Chemical Perturbation
124.2 Embedded Immunity
15319.3 Dampness, Mold, and Contested Exposure Illness
134.3 Enactive Immunity
15419.4 Dysbiosis, Biofilms, and Microbial Niche Disruption
144.4 Extended Immunity
15519.5 Sleep Disruption as Anti-Salugenic Exposure
154.5 Emotive and Evaluative Immunity
15619.6 Psychosocial Adversity and Threat Physiology
165. Preservation, Development, and Coherence: The Attractor Logic of Immune Life
15719.7 Climate Stress and Ecological Instability
175.1 Preservation: Boundary, Defence, Containment, and Memory
15819.8 Food-System Disruption and Metabolic-Immune Load
185.2 Development: Openness, Tolerance, Symbiosis, Growth, and Repair
15919.9 Exposure-Locks and Healing-Cycle Failure
195.3 Coherence: Flexible Movement Between Protection and Participation
16019.10 Avoiding Exposure Reductionism
205.4 Pathological Lock-In of the Attractors
16119.11 Clinical Translation
215.5 Clinical Meaning of the Attractor Logic
16219.12 Transition to CIRS as a Contested Case Study
22Part III. Health, Healing, and Phase-Locking
16320. CIRS as a Contested Case Study of Exposure-Linked Phase-Locking
236. Salutogenesis: Coherence, Meaning, and Resistance Resources
16420.1 Why CIRS Is Clinically Provocative
247. Naviaux’s Health Cycle and Healing Cycle
16520.2 Evidence-Strength Framing
257.1 The Health Cycle
16620.3 CIRS as an Exposure-Lock Pattern
267.2 The Healing Cycle
16720.4 What CIRS Should Not Become
277.3 Re-entry into the Health Cycle
16820.5 What CIRS Can Contribute
287.4 Disease as Failure of Re-entry
16920.6 Clinical Approach to Suspected Exposure-Linked Phase-Locking
298. Allostasis, Allostatic Load, and Immune Resilience
17020.7 CIRS and the Ethics of Uncertainty
308.1 Homeostasis and Allostasis
17120.8 Why the Larger Framework Does Not Depend on CIRS
318.2 Allostatic Load
17220.9 Transition to Immune Epidemiology
328.3 Immune Resilience
17321. Immune Epidemiology as Organism–Niche Incoherence
338.4 Phase Coherence
17421.1 Beyond Disease-by-Disease Fragmentation
348.5 Clinical Implications of Allostatic Reasoning
17521.2 Better Diagnosis and Real Increase
359. The Master Distinction: Adaptive Phase-Shifting versus Maladaptive Phase-Locking
17621.3 Barrier Disruption
369.1 The Immune-Metabolic Phase Cycle
17721.4 Microbiome and Virome Disruption
379.2 Adaptive Phase-Shifting
17821.5 Metabolic Overload
389.3 Maladaptive Phase-Locking
17921.6 Allostatic Burden
399.4 Phase-Locking and the Organism–Niche Relation
18021.7 Exposure Accumulation
409.5 Phase-State Clinical Reasoning
18121.8 Developmental Mismatch
419.6 The Ethical Meaning of Phase-Locking
18221.9 Climate and Ecological Instability
429.7 Transition to Mechanisms
18321.10 Reduced Health-Cycle Conditions
43Part IV. Molecular, Cellular, and Evolutionary Foundations
18421.11 Immune Disease as Signal, Not Blame
4410. Molecular Architecture: Sensors, Signals, and Regulons
18521.12 Public Health Implications
4510.1 Pattern-Recognition Receptors and Boundary Evaluation
18621.13 Transition to Clinical, Public Health, and Civilizational Implications
4610.2 Antigenicity, Adjuvanticity, and Context
187Part VII. Clinical, Public Health, and Civilizational Implications
4710.3 Inflammasomes and the Danger-Defence Transition
18822. Clinical Translation: Diagnosis as Phase-State Reasoning
4810.4 cGAS–STING and Nucleic-Acid Boundary Integrity
18922.1 The Limits of Diagnosis Alone
4910.5 Fc Receptors, Complement, and Immune-Complex Meaning
19022.2 Naming the Disease and the Lock
5010.6 Mechanosensors and the Immunology of Force
19122.3 Tissue Niche Assessment
5110.7 Core Signalling Pathways as Phase Regulators
19222.4 Developmental and Historical Reasoning
5210.8 Transcription-Factor Regulons and Immune-State Installation
19322.5 Exposure Ecology
5310.9 Molecular Phase-Locking
19422.6 Allostatic Burden and Regulatory Margins
5410.10 Clinical Meaning
19522.7 The Next Adaptive Transition
5511. Gene Regulatory Networks and Immune-Cell State Attractors
19622.8 Clinical Care as Structural Coupling
5612. Viral Memory, Virome, Mobile Genetic Elements, and Boundary-Crossing Information
19722.9 Practical Template for Phase-State Diagnosis
5712.1 Viral Infection as Boundary Perturbation
19822.10 Avoiding Misuse
5812.2 Endogenous Viral Elements and the Evolutionary Depth of Immunity
19922.11 Transition to Biomarkers
5912.3 The Virome and Microbial Gene Flow
20023. Biomarkers and Phase-State Medicine
6012.4 Exosomes, Extracellular Vesicles, and Intercellular Boundary-Crossing
20123.1 From Static Markers to Regulatory Profiles
6112.5 Horizontal Transfer, Symbiosis, and the Porous History of Life
20223.2 Immune Signatures
6212.6 Viral and Mobile-Element Boundary Locks
20323.3 Metabolic and Mitochondrial Markers
6312.7 Clinical Implications
20423.4 Resolution and Clearance Markers
6412.8 Transition to Immunometabolism
20523.5 Tissue Imaging and Structural Phase-State
6513. Immunometabolism and Epigenetic Memory
20623.6 Microbiome, Virome, and Exposure Markers
6613.1 Metabolism as Phase Selection
20723.7 Health-Cycle Re-Entry Markers
6713.2 Acetyl-CoA, Chromatin, and Inflammatory Readiness
20823.8 Biomarkers as Instruments, Not Possessions
6813.3 NAD⁺, Sirtuins, Repair, and Energetic Reserve
20923.9 Toward Phase-State Dashboards
6913.4 α-Ketoglutarate, Succinate, Fumarate, and Immune-State Bias
21023.10 Transition to Treatment
7013.5 SAM, Methylation, and Durable Immune Memory
21124. Treatment as Phase Restoration
7113.6 Lactate, Hypoxia, and the Inflamed Tissue Niche
21224.1 Suppression: Preventing Damage When Defence Becomes Destructive
7213.7 ROS, Redox Signalling, and Damage
21324.2 Resolution: Completing Inflammation
7313.8 Extracellular ATP and Danger-Energy Signalling
21424.3 Clearance: Removing Danger Material
7413.9 Trained Immunity as Metabolic-Epigenetic Memory
21524.4 Repair: Restoring Structure Without Overbuilding
7513.10 Immunometabolic Phase-Locking
21624.5 Reintegration: Returning to the Health Cycle
7613.11 Clinical Implications
21724.6 Exposure Removal and Niche Repair
7713.12 Transition to Mitochondria
21824.7 Clinical Care as Structural Coupling
7814. Mitochondria as Phase-Setting Organelles
21924.8 Minimum Sufficient Force
7914.1 Mitochondrial Allostasis
22024.9 Sequencing Care
8014.2 Mitochondria and Redox Coherence
22124.10 Integrating Conventional and Life-Coherent Treatment
8114.3 Mitochondrial DNA as Internal Danger Signal
22224.11 Avoiding Therapeutic Errors
8214.4 MAVS and Antiviral Signalling
22324.12 The Ethical Aim of Treatment
8314.5 Inflammasomes, Mitochondrial Stress, and Pyroinflammatory States
22424.13 Transition to Public Health
8414.6 Mitophagy and Clearance of Damaged Mitochondria
22525. Public Health as Protection of Health-Cycle Conditions
8514.7 Mitochondrial DAMPs and Sterile Inflammation
22625.1 Clean Air as Immune Protection
8614.8 Mitochondrial Conservation and Shutdown
22725.2 Safe and Healthy Housing
8714.9 Mitochondria, Repair, and Regeneration
22825.3 Food Systems and Metabolic-Immune Coherence
8814.10 Mitochondrial Phase-Locks
22925.4 Microbiome-Protective Policy
8914.11 Clinical Meaning
23025.5 Sleep-Protective Rhythms
9014.12 Transition to the Cell Danger Response
23125.6 Toxin Reduction and Chemical Safety
9115. Cell Danger Response, Salugenesis, and Incomplete Healing
23225.7 Climate Adaptation as Immune Prevention
9215.1 The Cell Danger Response as Protective Phase Shift
23325.8 Early-Life Protection
9315.2 Extracellular ATP and the Signal of Displaced Energy
23425.9 Equitable Access to Care
9415.3 From Inflammation to Proliferation to Differentiation
23525.10 Public Health as Anti-Phase-Locking
9515.4 Incomplete Salugenesis
23625.11 Avoiding Individualization of Public Health Failure
9615.5 Abnormal Persistence of Cell Danger Phases
23725.12 Public Health Dashboards for Immune Coherence
9715.6 Cell Danger Response and Chronic Fatigue States
23825.13 From Public Health to Civilizational Design
9815.7 Cell Danger Response and Fibrosis
23926. Civilizational Implications: Toward Life-Coherent Systems
9915.8 Cell Danger Response and Neuroimmune Sensitization
24026.1 Civilization as Extended Immune Niche
10015.9 Salugenesis and Clinical Care
24126.2 The Medicalization of Chronic Perturbation
10115.10 Limits of the Cell Danger Response Frame
24226.3 Economy as Immune Determinant
10215.11 Transition to Tissue Niches
24326.4 Law, Policy, and the Protection of Biological Margins
103Part V. Tissue Niches, Phase-Locks, and Disease Expression
24426.5 Technology and the Immune Field
10416. Tissue Niches and Disease-Specific Regulatory Attractors
24526.6 Education and Immune Literacy
10516.1 The Tissue Niche as Regulatory Field
24626.7 The Civil Commons as Immune Infrastructure
10616.2 Synovium: Inflammatory Memory in a Moving Joint
24726.8 Civilization as Salugenic or Anti-Salugenic
10716.3 Enthesis: Mechanical Stress and Immune Activation
24826.9 Chronic Immune Disease as Civilizational Feedback
10816.4 Airway and Sinus Mucosa: Barrier Alarm and Type 2 Locking
24926.10 Medicine’s Civilizational Role
10916.5 Skin: Visible Boundary, Microbial Ecology, and Social Surface
25026.11 Life-Coherent Systems
11016.6 Gut: Tolerance, Microbiome, Barrier, and Mucosal Healing
25126.12 Avoiding Overreach
11116.7 Vessel: Circulation, Immune Complexes, Endothelium, and Flow
25226.13 The Horizon of Immune Coherence
11216.8 Kidney: Filtration, Immune Deposition, and Silent Vulnerability
25326.14 Transition to Limits, Humility, and Conclusion
11316.9 Lung Interstitium: Gas Exchange, Repair, and Fibrotic Constraint
254Part VIII. Limits, Humility, and Conclusion
11416.10 Bone Marrow: Haematopoietic Memory and Systemic Readiness
25527. Evidence Strength, Limits, and Required Humility
11516.11 CNS and Neuroimmune Niches: Protection, Clearance, and Meaning
25627.1 The Framework Is Not Final Truth
11616.12 Tissue Attractors and Disease Form
25727.2 Categories Are Observer-Made
11716.13 Transition to Phase-Lock Taxonomy
25827.3 The Framework Does Not Replace Diagnosis
11817. Phase-Lock Taxonomy of Immune-Mediated Disease
25927.4 Not All Chronic Disease Is Immune Disease
11917.1 Recognition and Misrecognition Lock
26027.5 Avoiding Overstatement of CIRS and Exposure Claims
12017.2 Danger and Inflammasome Lock
26127.6 Avoiding Overstatement of Virome and Mobile-Element Claims
12117.3 Nucleic-Acid and Interferon Lock
26227.7 Distinguishing Metaphor from Measurable Biology
12217.4 Viral and Mobile-Element Boundary Lock
26327.8 Avoiding Patient Blame
12317.5 Barrier-Type 2 Lock
26427.9 Avoiding Anti-Biomedical Misuse
12417.6 Mechano-Microbial Enthesis/IL-17 Lock
26527.10 Avoiding Holistic Overreach
12517.7 Immune-Complex Vascular Lock
26627.11 Evidence Strength Across the Framework
12617.8 Trained-Immunity Lock
26727.12 Research Implications
12717.9 Immunodeficiency-Dysregulation Lock
26827.13 Clinical Cautions
12817.10 Resolution and Clearance-Failure Lock
26927.14 Patient Communication
12917.11 Repair-Overbuild and Fibrosis Lock
27027.15 Required Humility
13017.12 Neuroimmune and Allostatic Pain-Fatigue Lock
27128. Conclusion: Toward Organism-Centered Life-Coherent Systems Immunology
13117.13 Mixed Locks and Dominant Locks
272Appendix A. Phase-State Clinical Reasoning Template
13217.14 Summary of the Phase-Lock Taxonomy
273A.1 Conventional Diagnosis or Differential Diagnosis
13317.15 Transition to Clearance, Drainage, and Waste Removal
274A.2 Tissue Niche
13418. Clearance, Drainage, and Waste Removal
275A.3 Dominant Phase-Lock
13518.1 Efferocytosis: Quiet Removal of the Dead
276A.4 Sustaining Conditions
13618.2 Autophagy and Mitophagy: Intracellular Clearance
277A.5 Next Adaptive Transition
13718.3 Lymphatics: Drainage as Immune Infrastructure
278A.6 Monitoring Re-Entry
13818.4 Mucociliary Clearance: The Airway’s Removal System
279Glossary of Core Terms
13918.5 Glymphatic Clearance: Sleep, Brain, and Waste Removal
280Acknowledgements
14018.6 Immune Complexes and Filtration Burden
281Author Bio
14118.7 Crystals, Particles, and Persistent Material
282References Note
